What top creators are saying about SPDR S&P Biotech ETF(XBI)

Identified as a sector AI will disrupt or enhance through accelerated research.

Recommended as a stable core holding to capture AI-driven industry re-rating with lower risk.

Preferred for broader industry exposure to AI-driven drug discovery with better risk/reward.

Emerging as a major beneficiary of applied AI, which is accelerating drug discovery and collapsing medicine costs. The ETF is trending higher and outperforming the Nasdaq 100.

Suggested as a potential investment to gain exposure to the biotechnology sector, which is a key focus of the U.S. government's 'Genesis Mission' AI initiative, a massive potential catalyst for the sector.

The ETF is described as making a 'bearish to bullish reversal' with 'a lot of space to the upside,' driven by increased M&A activity and more attractive valuations in the biotech space.

The biotech index (XBI) is starting to climb back above the $100 mark, and its recovery suggests that institutional investors may be regaining confidence, which could signal a broader turnaround.

The ETF's chart is used as evidence that the biotech sector has been 'dead' for 15 years, making broad, passive investment in the sector a poor strategy.